Microbix Biosystems Earnings Call Balances Pressure, Progress

Microbix Biosystms ((TSE:MBX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Microbix Biosystems’ latest earnings call balanced cautious realism with measured optimism. Executives highlighted sequential revenue growth, expanding higher‑margin product lines, and operational gains, yet did not downplay the impact of a steep year‑over‑year revenue drop, margin compression, and continuing uncertainty in the Chinese market. Management framed current challenges as cyclical rather than structural.

Sequential Revenue Growth Amid a Difficult Comparison Base

Microbix reported Q1 fiscal 2026 revenue of $4.2 million, a 13% sequential increase that management said was in line with internal budgets. While still down roughly 30% versus last year’s elevated levels, the quarter‑over‑quarter improvement was presented as evidence that the business is stabilizing after a tough 2025 trough.

QAPs Expansion Reduces Concentration Risk

The company’s QAPs PT/EQA business delivered $1.9 million in revenue, up 15% year‑over‑year and now represents a growing share of overall sales. Management emphasized that QAPs revenues are more diversified across customers and geographies, which should help reduce dependence on any single large buyer and smooth out volatility.

Antigen Business Shows Underlying Recovery Ex‑China

While headline antigen sales dropped sharply year‑over‑year, management noted that excluding China, the antigen segment grew about 5% quarter‑over‑quarter. This suggests that demand from non‑Chinese customers is recovering, even as the company works through a temporary collapse in orders from its China distributor.

Cash Collections Bolster Balance Sheet

Microbix ended January with $10.6 million in cash, up $1.5 million from December after collecting $3.3 million during the month. Executives stressed that a spike in accounts receivable at quarter‑end created a temporary working capital drag but has since largely unwound, easing concerns about liquidity.

Recombinant Antigen Launch Targets Margin and Supply Gains

The company has brought recombinant antigen production in‑house and launched its first commercial recombinant product, a SARS‑CoV‑2 viral capsid antigen. This product is already being used in Microbix’s own QAPs and other offerings and is expected to strengthen supply‑chain security while supporting margin improvement over time.

New Client Wins Signal Market Expansion

Management highlighted new client programs in molecular pathology and point‑of‑care genetics, including relationships with Sekisui in the U.S. and Seegene in Mexico. A notable win was adding the College of American Pathologists, which is expected to reach six figures in revenue in 2026 and could scale into a meaningful seven‑figure account over time.

Operational Efficiencies Aim to Restore Margins

The company reported better manufacturing throughput, higher yields, and a reduced testing burden, supported by expanded electronic quality management systems. These initiatives are designed to lower unit production costs and expand gross margins once quarterly revenues climb back above the breakeven band.

Therapeutics Program Kinlytic Moves Forward with FDA

Microbix’s Kinlytic thrombolytic program continues in partnership with Sequel, with management describing recent FDA feedback on modernization as uncontroversial. Parallel work on drug substance and drug product is ongoing, with a supplemental biologics filing targeted for late 2027, framing Kinlytic as a longer‑dated but potentially significant value driver.

Share Buybacks Underscore Confidence

The company renewed its normal course issuer bid and repurchased roughly 700,000 shares in Q1, totaling around 1 million shares to date. With buybacks currently running at about 15,000 shares per day, well below the allowed maximum, management positioned the program as both anti‑dilutive and a signal of confidence in intrinsic value.

Year‑Over‑Year Revenue Drop Driven by China Collapse

Despite sequential improvement, Q1 revenues fell about 30% year‑over‑year, largely due to the disappearance of sales through the Chinese distributor. Management quantified the China shortfall as more than $2 million relative to prior periods, stressing that this remains the single largest driver of the headline decline.

Antigen Sales Hit Hard by China Distributor Inactivity

Antigen revenues were down 49% year‑over‑year, again primarily due to the lack of distributor‑driven sales into China. The company underscored that underlying demand elsewhere is intact, but the absence of Chinese orders has materially skewed both total revenue and the apparent performance of the antigen business.

Gross Margin Compression from Subscale Volumes

Gross margins came in well below last year and internal expectations, as fixed overhead was spread across a smaller production base. Management reiterated that margins should improve meaningfully once quarterly revenues move above roughly $5.5 million, where the business crosses its breakeven range and begins to leverage fixed costs.

Controlled Net Loss and Seasonal Cost Pattern

Microbix posted a net loss of about $1.2 million in Q1 and consumed cash during the quarter, though executives described the loss as controlled and in line with planning. They also noted that operating expenses were at or below expectations and seasonally lower in Q1, with some increase anticipated in Q2 and Q3.

Quarter‑End Receivables Spike Seen as Timing Issue

Accounts receivable more than doubled versus Q4, creating a sizable working capital draw and contributing to the quarter’s cash usage. Management argued this was mainly timing‑related, pointing to the $3.3 million collected in January as evidence that billing and collections are functioning normally.

Persistent China Uncertainty Weighs on Near‑Term Outlook

Sales into China remain very low with limited visibility on when demand will normalize, and management now expects any meaningful pickup to show only in late summer or early fall. This creates an overhang on short‑term revenue, underscoring the importance of Microbix’s efforts to diversify away from China‑centric antigen volumes.

Profitability Path Clear but Timing Still Uncertain

The company continues to target breakeven at quarterly revenues of roughly $5.5 million to $6.0 million but cautioned that a profitable Q4 is not guaranteed. Management indicated that returning to sustained profitability will depend heavily on the pace of new business wins, order timing, and the speed of recovery in key markets.

Forward‑Looking Guidance and Management Outlook

For fiscal 2026, Microbix is modeling full‑year revenue roughly 30% above the 2025 trough, implying about $18 million to $19 million versus Q1’s $4.2 million run‑rate. Executives expect gross margins to repair as volumes scale, with QAPs growth, recombinant antigen commercialization, and operational efficiencies doing the heavy lifting, while China remains a wildcard and Kinlytic a longer‑term catalyst.

Microbix’s call painted a picture of a company working through a sharp external shock while quietly rebuilding operational and strategic strength. For investors, the story hinges on whether revenue can climb back into the breakeven band as planned, allowing today’s efficiency gains, product diversification, and new client relationships to translate into restored margins and renewed earnings power.